Physician profile
Ryan Strasser
NPI 1962016394
$16,719.33
in general payments reported to CMS, 2019-2025
28 companies · $4,181 in 2025
The $4,181 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $916 · 2022: $1,484 · 2023: $5,024 · 2024: $5,115 · 2025: $4,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,575.99 |
| Education | $743.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,433.42 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $2,320.78 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,722.16 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $1,272.23 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,163.01 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $1,028.39 | 2021-2025 | |
| Incyte Corporation | $845.77 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $793.27 | 2022-2025 | |
| Ucb, INC. | $772.40 | 2023-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $696.61 | 2023-2025 | Zoryve |
| Pfizer INC. | $660.82 | 2022-2025 | |
| Dermavant Sciences, INC. | $595.55 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $480.73 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $396.73 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $338.51 | 2021-2024 | Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $309.49 | 2024-2025 | Vtama, Hadlima, Nexplanon |
| Sanofi-Aventis U.S. LLC | $241.94 | 2021-2024 | |
| Amgen INC. | $145.49 | 2022-2025 | Otezla, Otezla |
| Biofrontera INC. | $135.86 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.56 | 2022-2023 | Spevigo |
| Epi Health, LLC | $88.20 | 2021-2022 | |
| Strata Skin Sciences, INC. | $73.41 | 2024-2025 | Xtrac |
| Fresenius Kabi USA, LLC | $25.62 | 2024 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.85 | 2025 | Arazlo |
| Kyowa Kirin, INC. | $19.23 | 2022 | |
| Journey Medical Corporation | $16.08 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.03 | 2025 | Nuzyra |
| Helsinn Therapeutics (U.S.), INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Strasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.